Fondaparınux Versus Nadroparın for Preventıon of Venous Thromboembolısm After Electıve Hıp and Knee Arthroplasty

Overview

Journal Curr Ther Res Clin Exp

Specialty Pharmacology

Date 2014 Jan 4

PMID 24384784

Citations 4

Authors

Mahmut Argun

Mithat Oner

Mehmet Saglamoglu

Ibrahim Karaman

Ahmet Guney

Mehmet Halici

Ibrahim Halil Kafadar

Affiliations

Soon will be listed here.

Abstract

Objective: To evaluate the efficacy and safety of fondaparinux compared with nadroparin for prevention of venous thromboembolism after arthroplasty.

Patients And Methods: One hundred fifteen patients were randomized into 2 treatment groups. Patients were given fondaparinux in Group I and nadroparin in Group II. Measurements were performed on Days 1, 5, and 21. The wound area was assessed with a subjective visual analog scale.

Results: The blood counts, clinical biochemical tests, and coagulation tests (ie, thrombin time, partial thromboplastin time, activated partial thromboplastin time, fibrinogen, prothrombin time-International Normalized Ratio, and antithrombin III activity) did not show statistically significant differences between Group I and Group II. In both study groups, anti-factor Xa activities increased significantly on the fifth and 21st day. The scores of the subjective visual analog scale showed significance on Day 21.

Conclusions: Our results confirm the safety and efficacy of both fondaparinux and nadroparin for prophylaxis after major orthopedic surgery.

Citing Articles

Efficacy of 11 anticoagulants for the prevention of venous thromboembolism after total hip or knee arthroplasty: A systematic review and network meta-analysis.

Huang Z, Xu X, Xu D, Zhao P, Zou M Medicine (Baltimore). 2023; 102(2):e32635.

PMID: 36637921 PMC: 9839234. DOI: 10.1097/MD.0000000000032635.

Fondaparinux Sodium Compared With Low-Molecular-Weight Heparins for Perioperative Surgical Thromboprophylaxis: A Systematic Review and Meta-analysis.

Kumar A, Talwar A, Farley J, Muzumdar J, Schommer J, Balkrishnan R J Am Heart Assoc. 2019; 8(10):e012184.

PMID: 31070069 PMC: 6585337. DOI: 10.1161/JAHA.119.012184.

Pentasaccharides for the prevention of venous thromboembolism.

Dong K, Song Y, Li X, Ding J, Gao Z, Lu D Cochrane Database Syst Rev. 2016; 10:CD005134.

PMID: 27797404 PMC: 6463830. DOI: 10.1002/14651858.CD005134.pub3.

Fatal intrahepatic hemorrhage after nadroparin use for total hip arthroplasty.

Ventura F, Bonsignore A, De Stefano F, Pizzorno E, Palmiere C Forensic Sci Med Pathol. 2014; 10(4):619-22.

PMID: 25108423 DOI: 10.1007/s12024-014-9593-0.

References

Bauer K, Hawkins D, Peters P, Petitou M, Herbert J, van Boeckel C . Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents - the selective factor Xa inhibitors. Cardiovasc Drug Rev. 2002; 20(1):37-52. DOI: 10.1111/j.1527-3466.2002.tb00081.x. View

Lensing A, Prins M, Davidson B, Hirsh J . Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch Intern Med. 1995; 155(6):601-7. View

McMillan W, McCarthy W, Lin S, Matsumura J, Pearce W, Yao J . Perioperative low molecular weight heparin for infrageniculate bypass. J Vasc Surg. 1997; 25(5):796-801; discussion 801-2. DOI: 10.1016/s0741-5214(97)70208-8. View

Turpie A, Bauer K, Eriksson B, Lassen M . Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med. 2002; 162(16):1833-40. DOI: 10.1001/archinte.162.16.1833. View

Fareed J, Jeske W, Hoppensteadt D, Clarizio R, Walenga J . Low-molecular-weight heparins: pharmacologic profile and product differentiation. Am J Cardiol. 1998; 82(5B):3L-10L. DOI: 10.1016/s0002-9149(98)00105-2. View

Nicolaides A, Breddin H, Fareed J, Goldhaber S, Haas S, Hull R . Prevention of venous thromboembolism. International Consensus Statement. Guidelines compiled in accordance with the scientific evidence. Int Angiol. 2001; 20(1):1-37. View

White R, Romano P, Zhou H, Rodrigo J, Bargar W . Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med. 1998; 158(14):1525-31. DOI: 10.1001/archinte.158.14.1525. View

Sikorski J, Hampson W, Staddon G . The natural history and aetiology of deep vein thrombosis after total hip replacement. J Bone Joint Surg Br. 1981; 63-B(2):171-7. DOI: 10.1302/0301-620X.63B2.7217137. View

Yoo M, Kang C, Kim Y, Kim S . A prospective randomized study on the use of nadroparin calcium in the prophylaxis of thromboembolism in Korean patients undergoing elective total hip replacement. Int Orthop. 1997; 21(6):399-402. PMC: 3619564. DOI: 10.1007/s002640050194. View

10.

Turpie A, Gallus A, Hoek J . A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med. 2001; 344(9):619-25. DOI: 10.1056/NEJM200103013440901. View

11.

Frostick S . Death after joint replacement. Haemostasis. 2001; 30 Suppl 2:84-7; discussion 82-3. DOI: 10.1159/000054170. View

12.

Warwick D, Harrison J, Glew D, Mitchelmore A, Peters T, Donovan J . Comparison of the use of a foot pump with the use of low-molecular-weight heparin for the prevention of deep-vein thrombosis after total hip replacement. A prospective, randomized trial. J Bone Joint Surg Am. 1998; 80(8):1158-66. DOI: 10.2106/00004623-199808000-00009. View

13.

Paiement G, Wessinger S, Harris W . Survey of prophylaxis against venous thromboembolism in adults undergoing hip surgery. Clin Orthop Relat Res. 1987; (223):188-93. View

14.

Singelyn F, Verheyen C, Piovella F, Van Aken H, Rosencher N . The safety and efficacy of extended thromboprophylaxis with fondaparinux after major orthopedic surgery of the lower limb with or without a neuraxial or deep peripheral nerve catheter: the EXPERT Study. Anesth Analg. 2007; 105(6):1540-7, table of contents. DOI: 10.1213/01.ane.0000287677.95626.60. View

15.

Samama M, Poller L . Contemporary laboratory monitoring of low molecular weight heparins. Clin Lab Med. 1995; 15(1):119-23. View